Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses - Textual (Details)

v2.4.0.8
Acquisitions, Investments, and Licenses - Textual (Details)
3 Months Ended 6 Months Ended 1 Months Ended 0 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended 0 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended
Jun. 30, 2014
USD ($)
Jun. 30, 2013
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2013
USD ($)
Dec. 31, 2013
USD ($)
Jun. 30, 2012
SciVac
Variable Interest Entity, Primary Beneficiary
USD ($)
member
Jun. 30, 2014
SciVac
Variable Interest Entity, Primary Beneficiary
USD ($)
May 16, 2014
Common stock investments, available for sale
Rate
Jan. 16, 2014
Biozone
Equity Method Investee
USD ($)
Jan. 03, 2014
Biozone
Equity Method Investee
Jan. 02, 2014
Biozone
Equity Method Investee
Jan. 16, 2014
Biozone
Equity Method Investee
Jan. 03, 2014
Biozone
Equity Method Investee
Series B Convertible Preferred Stock
Jan. 02, 2014
Biozone
Equity Method Investee
Series B Convertible Preferred Stock
Oct. 31, 2013
ARNO
USD ($)
Oct. 31, 2013
ARNO
Equity Method Investee
USD ($)
Dec. 31, 2013
Neovasc
USD ($)
Dec. 31, 2011
Neovasc
USD ($)
Jan. 31, 2014
Pharmsynthez
Apr. 30, 2013
Pharmsynthez
USD ($)
Apr. 30, 2013
Pharmsynthez
RUB
Jun. 30, 2014
Pharmsynthez
USD ($)
Mar. 31, 2013
RXi Pharmaceuticals Corporation
USD ($)
Oct. 31, 2013
Zebra
USD ($)
Oct. 31, 2013
Zebra
Series A Preferred Stock
Oct. 31, 2013
Zebra
Restricted Stock
May 16, 2014
Senesco
Common stock investments, available for sale
May 16, 2014
Senesco
Common stock investments, available for sale
May 16, 2014
Fabrus
Common stock investments, available for sale
Oct. 31, 2013
One Year Warrants
ARNO
Equity Method Investee
Oct. 31, 2013
Five Year Warrants
ARNO
Equity Method Investee
Apr. 17, 2014
Inspiro
USD ($)
Apr. 17, 2014
Inspiro
USD ($)
Aug. 31, 2013
OPKO Biologics
USD ($)
Mar. 31, 2013
OPKO Renal
USD ($)
Business Acquisition [Line Items]                                                                      
Inspiro stock purchase agreement                                                                 100.00%    
Cash paid at closing date           $ 700,000                                                   $ 1,500,000      
Common stock value                                                                 8,600,000 540,600,000 146,900,000
Number of trading days                                                               10 days     10 days
Stock price                                                                 $ 8.57 $ 8.49 $ 7.16
In process research and development 10,055,000 0 10,055,000 0                                                       10,100,000      
Shares conversion ratio                                                                   0.9951  
Delivery of common stock                                                               999,556   63,670,805 20,517,030
Options and warrants outstanding (shares)                                                                   7,889,265  
Fair value of warrants outstanding                             3,600,000                                     46,100,000  
Percentage of ownership held by chairman                                                                   5.00%  
Percentage of ownership held by directors                                                                   5.00%  
Business acquisition share price on shares issue                                                               $ 9.00     $ 4.87
Amount payable in cash or shares on achieving milestones for acquiring a product in development                                                                     190,000,000
Contingent consideration 72,900,000   72,900,000   71,600,000                                                           47,700,000
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued                         1,000,000 1,000,000                                          
Stock Conversion, Common Shares Issued upon Conversion                   205.08308640 205.08308640                                                
Invested in common shares                 500,000             2,000,000 1,200,000 2,000,000         2,500,000 2,000,000                      
Warrants to purchase common shares                       1,000,000           1,000,000                       833,333 833,333        
Class of Warrant or Right, Exercise Price of Warrants or Rights                       0.50                                   2.40 4.00        
Warrants expiration period                                   2 years                       1 year 5 years        
Number of shares purchased                                   2,000,000   13,600,000 13,600,000   17,241,380                        
Investment Warrants, Exercise Price                                   $ 1.25                                  
Asset Purchase Agreement                                       9,600,000                              
Number of share options received in purchase agreement                                       12,000,000 12,000,000                            
Proceeds to be received from sale of proprietary technology                                       8,100,000 265,000,000                            
Shares Received In Satisfaction of Notes Receivable                                     12,000,000                                
Deferred revenue 8,300,000   8,300,000   8,300,000                             9,500,000                              
Period for development of technology                                       3 years 3 years                            
Deferred revenue received from collaboration agreement                                           1,400,000                          
Revenue related to our license agreements                                           500,000                          
Revenue collaboration agreement, offset to research and development                                           800,000                          
Issue of common stock shares                                             50,000,000                        
Milestone payments                                             50,000,000                        
Asset purchase agreement financing for Rxi                                             16,400,000                        
New Options Ratio               0.376939                                                      
Conversion of Stock, Shares Converted                                                     80,000                
Shares, Outstanding                                                         1,159,380            
Equity Method Investment, Third Party Purchase of Investment, Conversion of Shares, Shares Issued in New Entity                                                     437,016                
Investment Owned, Balance, Shares                       1,000,000       833,333                 840,000     517,016              
Number of Shares Warrants Acquired in Equity Method Investment                                                     267,927                
Cocrystal on a fully diluted basis           50.00%                                                          
Additional working capital             2,600,000                                                        
Number of members of board of directors           5                                                          
Number of members of board of directors appointed by reporting entity           3                                                          
Percent of board of directors appointed by reporting entity           60.00%                                                          
Shares Received As Gift                                                   900,000                  
Equity Method Investment, Ownership Percentage                                                 23.50%                    
Total assets of equity method investees 131,400,000   131,400,000                                                                
Total liabilities of equity method investees 17,700,000   17,700,000                                                                
Net losses of equity method investees     $ 25,200,000